A Kansheng and a joint announcement by Nuo Cheng Jianhua, and both companies and their joint venture jointly and Prolium Bioscience reached a licensing agreement to authorize Prolium to develop and commercialize CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the terms of the protocolo, Prolium will obtain the rights to develop, register, produce and commercialize ICP-B02 in the global non-oncology field and the oncology field outside Asia. Nuo Cheng Jianhua and Kansheng will receive a total payment of up to US$520 million, including initial payment and recent payment, as well as additional payments for achieving clinical development, registration and commercialization milestones, and both parties will receive a minority equity stake in Prolium. At the same time, Nuo Cheng Jianhua and Kansheng will also receive tiered royalty fees for the net sales of future products.
Ver original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
A Conoah e a Nochein Jianhua anunciaram conjuntamente a concessão de licenças autorizadas para a dupla resistência CD20xCD3 e Prolium.
A Kansheng and a joint announcement by Nuo Cheng Jianhua, and both companies and their joint venture jointly and Prolium Bioscience reached a licensing agreement to authorize Prolium to develop and commercialize CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the terms of the protocolo, Prolium will obtain the rights to develop, register, produce and commercialize ICP-B02 in the global non-oncology field and the oncology field outside Asia. Nuo Cheng Jianhua and Kansheng will receive a total payment of up to US$520 million, including initial payment and recent payment, as well as additional payments for achieving clinical development, registration and commercialization milestones, and both parties will receive a minority equity stake in Prolium. At the same time, Nuo Cheng Jianhua and Kansheng will also receive tiered royalty fees for the net sales of future products.